What is Scout Bio?
Scout Bio is a pioneering biotechnology enterprise dedicated to revolutionizing the standard of care for companion animals. By utilizing advanced AAV vector technology, the company develops one-time gene therapies and monoclonal antibodies designed to treat chronic health conditions that have historically lacked effective, long-term solutions. Through a strategic partnership with the University of Pennsylvania's Gene Therapy Program, Scout Bio integrates academic research excellence with commercial scalability. The company serves a critical market need, providing veterinary professionals and pet owners with innovative therapeutic options that improve the quality of life for animals suffering from persistent ailments. Its market position is defined by its unique focus on high-impact, durable treatments that simplify the management of complex veterinary diseases.
How much funding has Scout Bio raised?
Scout Bio has raised a total of $62.3M across 2 funding rounds:
Series A
$9.3M
Series B
$53M
Series A (2018): $9.3M with participation from Frazier Healthcare Partners
Series B (2021): $53M led by OrbiMed, Digitalis Ventures, Frazier Healthcare Partners, and RiverVest Venture Partners
Key Investors in Scout Bio
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and life sciences to support companies at various stages of development.
Digitalis Ventures
Digitalis Ventures leverages deep technical and domain expertise to invest in biotechnology and technology-enabled solutions aimed at improving human and animal health.
RiverVest Venture Partners
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs through a commitment to science, strategy, and innovation.
What's next for Scout Bio?
With the recent capital injection, Scout Bio is poised to transition from a research-heavy development phase into a more robust commercialization and clinical expansion stage. The company will likely prioritize the advancement of its lead therapeutic candidates through regulatory milestones while expanding its manufacturing capabilities to support broader market adoption. Strategic focus will remain on deepening its intellectual property portfolio and strengthening its collaborative network within the veterinary medical community. As the firm continues to scale, it is expected to explore new therapeutic indications, further solidifying its role as a leader in the veterinary biotechnology space and setting a new benchmark for how chronic diseases are managed in the pet health industry.
See full Scout Bio company page
